The maker of Lotronex, a popular drug for women with irritable bowel syndrome, pulled it off the market Tuesday amid reports of potentially fatal side effects. About 300,000 patients have taken the drug since Glaxo Wellcome began selling it March 15, according to the company. The drug was approved only for women for whom diarrhea is the main symptom of irritable bowel syndrome (IBS), a chronic problem characterized by abdominal pain, diarrhea or constipation. It is the seventh drug in about three years to be taken off the market.
By Nov. 10, the Food and Drug Administration had received reports of at least three deaths that appeared to be linked to the drug, says Victor Raczkowski, deputy director of the FDA drug evaluation office that reviewed Lotronex.
The deaths occurred in women who had developed ischemic colitis - an inflammation of the large bowel from a lack of blood flow -- or severe constipation after taking Lotronex, Raczkowski says. By Nov. 10, he says, the FDA had received reports of 49 cases of ischemic colitis and 21 cases of severe constipation in Lotronex users.
After reviewing the case reports, the FDA advisory committee that had approved Lotronex urged the agency to require a patient-friendly "medication guide" explaining potential risks. In early September, Lotronex became the first drug to carry such a guide. Glaxo Wellcome also revised Lotronex labeling for health professionals to reflect the risks and mailed out letters to alert doctors of the change.
But many of the serious side effects occurred in women who were taking the drug appropriately, Raczkowski says, leading the FDA to continue discussions with the manufacturer about how to manage risks.
The agency suggested restricting Lotronex's use to women with the most severe diarrhea, Raczkowski says. But Richard Kent, chief medical officer at Glaxo Wellcome, says that some of the FDA's proposed restrictions were "non-doable."
That left the company with no choice but to pull Lotronex off the market, Kent says. "We view this as a fairly sad day for women who suffer with IBS," he says. "These women are going to have to go back to old, unproven therapies that hadn't worked in the past."
But consumer advocate Sidney Wolfe, director of Public Citizen's Health Research Group, notes that clinical trials of Lotronex showed it to be barely more effective than a sugar pill.
"The drug doesn't have any unique advantage that really overcomes the deaths and injuries it is causing," says Wolfe, whose group had asked the FDA to ban Lotronex. "This drug should never have been approved."
Wolfe, a longtime critic of the FDA, charges that the agency "bends over backward" to allow drugs to remain on the market.
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.